Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2013 Jul;11(7):1300-9.
doi: 10.1111/jth.12259.

Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study

C H Miller  1 , A S Rice, B Boylan, A D Shapiro, S R Lentz, B M Wicklund, F M Kelly, J M Soucie; Hemophilia Inhibitor Research Study Investigators
Collaborators, Affiliations
Comparative Study

Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study

C H Miller et al. J Thromb Haemost. 2013 Jul.

Abstract

Background: Detection and validation of inhibitors (antibodies) to hemophilia treatment products are important for clinical care, evaluation of product safety and assessment of population trends.

Methods: Centralized monitoring for factor VIII (FVIII) inhibitors was conducted for patients in the Hemophilia Inhibitor Research Study using a previously reported modified Nijmegen-Bethesda clotting assay (NBA), a chromogenic Bethesda assay (CBA) and a novel fluorescence immunoassay (FLI).

Results: NBA and CBA were performed on 1005 specimens and FLI on 272 specimens. CBA was negative on 880/883 specimens (99.7%) with Nijmegen-Bethesda units (NBU) < 0.5 and positive on 42/42 specimens (100%) with NBU ≥ 2.0 and 43/80 specimens (53.8%) with NBU 0.5-1.9. Among specimens with positive NBA and negative CBA, 58.1% were FLI negative, 12.9% had evidence of lupus anticoagulant, and 35.5% had non-time-dependent inhibition. CBA and FLI were positive on 72.4% and 100% of 1.0-1.9 NBU specimens and 43.1% and 50.0% of 0.5-0.9 NBU specimens. FLI detected antibodies in 98.0% of CBA-positive and 81.6% of NBA-positive specimens (P = 0.004). Among 21 new inhibitors detected by NBA, five (23.8%) with 0.7-1.3 NBU did not react in CBA or FLI. Among previously positive patients with 0.5-1.9 NBU, 7/25 (28%) were not CBA or FLI positive. FLI was positive on 36/169 NBU-negative specimens (21.3%).

Conclusions: FVIII specificity could not be demonstrated by CBA or FLI for 26% of inhibitors of 0.5-1.9 NBU; such results must be interpreted with caution. Low titer inhibitors detected in clot-based assays should always be repeated, with consideration given to evaluating their reactivity with FVIII using more specific assays.

Keywords: factor VIII; factor VIII inhibitor; hemophilia A; immunology and fluorescence immunoassay.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Correlation of Nijmegen-Bethesda Units (NBU) and Chromogenic Bethesda Units (CBU) in specimens with ≥2.0 NBU. Two points were outside the range of the graph at NBU 207.6, CBU 108.8 and NBU 688.0, CBU 512.0.
Figure 2
Figure 2
Results of fluorescence immunoassay in fluorescence immunoassay units (FLIU) in normal individuals (n=83) and hemophilia patients with negative Nijmegen-Bethesda assay results (n=169).
Figure 3
Figure 3
Comparison of positivity rates of Chromogenic Bethesda Assay and Fluorescence Immunoassay (FLI) with Nijmegen-Bethesda Units. A. All specimens. B. Specimens with NBU<1.0.
Figure 4
Figure 4
Dilution curves for inhibitors of 13.3 Nijmegen-Bethesda units (NBU) (A), 30.8 NBU (B), and 48.5 NBU (C). Solid lines represent the Nijmegen-Bethesda Assay. Dashed lines represent the Chromogenic Bethesda Assay with the cutoff for positivity (dotted line) at 70% residual activity (0.5 NBU). D. Dilution curve of factor VIII (FVIII) activity assay. Solid line represents FVIII clotting assay. Dashed line represents FVIII chromogenic assay.
Figure 5
Figure 5
Dilution curves of the fluorescence immunoassay. The dotted line represents the cutoff for assay positivity at fluorescence immunoassay units (FLIU) =0.466.
Figure 6
Figure 6
Nijmegen-Bethesda Assay (NBA) dilution curves of inhibitor plasmas. A: Concordant specimens [positive NBA and positive Chromogenic Bethesda Assay (CBA)].B: Discordant specimens (positive NBA and negative CBA). Dashed lines at 75% and 25% residual factor VIII activity define the interval within which NBU are calculated, representing the 0.4 and 2.0 NBU levels, respectively.
See this image and copyright information in PMC

References

    1. Biggs R, Bidwell E. A method for the study of antihaemophilic globulin inhibitors with reference to six cases. Br J Haematol. 1959;5:379–95. - PubMed
    1. Nuss R, Jacobson L, Hathaway WE, Manco-Johnson M Recombinate PUP Study Group. Evidence for antiphospholipid antibodies in children with factor VIII inhibitors. Thromb Haemost. 1999;82:1559–60. - PubMed
    1. Blanco AN, Peirano AA, Grosso SH, Gennari LC, Perez Blanco R, Lazzari MA. A chromogenic substrate method for detecting and titrating anti-factor VIII antibodies in the presence of lupus anticoagulants. Haematologica. 2002;87:271–8. - PubMed
    1. Shaw PH, Reynolds S, Gunawardena S, Krishnamurti L, Ritchey AK. The prevalence of bleeding disorders among healthy pediatric patients with abnormal preprocedural coagulation studies. J Pediatr Hematol Oncol. 2008;30:135–41. - PubMed
    1. Manco-Johnson MJ, Nuss R, Jacobson LJ. Heparin neutralization is essential for accurate measurement of factor VIII activity and inhibitor assays in blood samples drawn from implanted venous access devices. J Lab Clin Med. 2000;136:74–9. - PubMed

Publication types

MeSH terms